An interventional study of Laser with DCD Pre- and Post-Cooling and Laser with Standard DCD Pre-Cooling Only in Rosacea, Scars and Port Wine Capillary Malformations, sponsored by University of California, Irvine. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by University of California, Irvine · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies in Rosacea with a site in United States — 11 open to participants now, 12 under way, none of them phase 3. Rosacea · United States.
Among the 147 studies in Rosacea with a site in United States, this one is the 99th largest by planned enrollment of the 139 interventional ones that give a count, is one of 4 that started in 2026, is one of 25 with no phase, reaches primary completion later than 10 of the 11 other live ones, and was the 146th registered.
234 studies on the registry are indexed under Rosacea; 24 are open to participants now.
Browse Rosacea studies →11 of the 147 studies in Rosacea with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Bulgaria, Canada and 6 more countries
Ages 18+
Brigham and Women's Hospital · Sites in United States
Ages 18+
Narrows Institute for Biomedical Research · Sites in United States
Ages 18+ · Healthy volunteers
University of Miami · Sites in United States
Ages 18+
Wright State University · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Rosacea studies recruiting now, 10 (59%) set no upper age limit and 6 (35%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 44 · Phase 3 34 · Phase 4 20
First in 2002; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 61 across 201 interventional studies indexed under Rosacea.
Median enrollment 70 across the 139 interventional studies, 236 across the 8 observational. Of the 127 that completed or were terminated, 76 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
99 of 147 have an industry lead sponsor. The 10 most frequent:
University of California, Irvine is the lead sponsor of 478 studies on the registry; 99 are open to participants now.
Of its 41 completed or terminated interventional studies of FDA-regulated products, 30 (73%) have results posted.
University of California, Irvine has 3 studies filed under Rosacea — fewer than ten, so there is no comparison to draw.
4 of the studies in Rosacea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07443202Tarsus Pharmaceuticals, Inc.Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE) | 2026-12-31 |
| NCT07946250BrocShot IncA Clinical Trial to Evaluate the Effects of Broc Shot Capsules on Skin Appearance and Comfort in Adults With Reactive, Blemish-Prone, or Hormonally Affected Skin | 2027-01 |
| NCT06801717University of MiamiRosacea Radiofrequency Microneedling | 2027-07-01 |
| NCT04108897Johns Hopkins UniversityAnalysis of the Microbiome in Rosacea | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 147 studies in Rosacea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this prospective clinical study is to evaluate pulsed dye laser treatment parameters on the clearance of vascular indications, including rosacea and port wine capillary malformations. The main question it aims to answer is:
- Does the use of post-cooling, compared with no post-cooling, affect patient-reported pain scores and treatment outcomes after one treatment session?
Participants will:
This is an exploratory pilot study. The purpose of this research is to understand how to best use the Vbeam Pro Laser System for the treatment of vascular indications, including rosacea and port wine capillary malformations. The present protocol for this pilot study provides a critical pathway to implement a comparison of these laser settings. The qualitative measurements of improvement and tolerability will be quantified using questionnaires. Key characteristics will be summarized for all participants and tabulated by skin condition. Assessment of efficacy will occur after 1 treatment session.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Laser with DCD Pre- and Post-Cooling
Device: Laser with Standard DCD Pre-Cooling Only
Study subject will undergo informed consent procedure, eligibility screening, and enrollment to receive treatment to one or more treatment areas depending on the presenting condition and principal investigator assessment. Study subject may receive 1-3 treatments within the study with 4-12 weeks between each treatment visit. Two test areas will be determined in the area(s) of the vascular condition. Each lesion will serve as its own control, since it is divided in half and each side receives a different set of laser settings. The following laser settings will be applied: Area 1: Spot size 7-15mm; pulse duration 1.5-10 ms; fluence 5-8 j/cm2; cooling settings 10-30/20-30/10-20 ms
Study subject will undergo informed consent procedure, eligibility screening, and enrollment to receive treatment to one or more treatment areas depending on the presenting condition and principal investigator assessment. Study subject may receive 1-3 treatments within the study with 4-12 weeks between each treatment visit. Two test areas will be determined in the area(s) of the vascular condition. Each lesion will serve as its own control, since it is divided in half and each side receives a different set of laser settings. The following laser settings will be applied: Area 2: Spot size 7-15mm; pulse duration 1.5-10 ms; fluence 5-8 j/cm2; cooling settings 10-30/20-30/0 ms
The Effect of Pre- and Post-Cooling on Patient Reported Discomfort as Evaluated by Responses to Two-Part Post-Treatment Questionnaire
Patients will have a portion of their treatment area(s) treated with both pre-cooling and post-cooling bursts. Note that pre-cooling (a cooling burst delivered immediately prior to the laser pulse) will be used for all treatments across all patients. A difference in tolerability is defined as a difference in at least 1 between the two treatments. The questionnaire assesses the following (only part 1 is used for tolerability): * Part 1 of questionnaire: Immediately following each treatment session, patients will rate their pain/discomfort using a 0-10 scale (0 meaning no pain, 10 meaning severe pain). A difference in tolerability between types of treatment will be considered a difference in 1 or more on this scale. * Part 2 of questionnaire: Patient will be contacted up to 72 hours after treatment to report potential development of adverse effects including swelling, bruising, scabbing, and blistering on a 0-4 scale (0 meaning no effects, 4 meaning severe effects).
Time frame: From date of first treatment until study completion, assessed up to 52 weeks.
Patient-Reported Evaluation of Improvement as Assessed by Participant Questionnaire
At the participants' final follow-up visit, they will complete a final questionnaire to assess if there is any difference in improvement between treatment area(s). Patient-reported improvement will be defined as any positive change in appearance, texture and/or global improvement score greater than zero.
Time frame: From date of first treatment until study completion, assessed up to 52 weeks.
Blinded Physician Evaluation
Blinded physicians will assess whether there is any difference in improvement between treatment areas(s).
Time frame: Up to 52 weeks.
Safety and Adverse Events Documented by The Clinician and Self-Reported by The Patient
Adverse events will be tabulated by type, frequency, severity, treatment relationship, actions taken, and outcome. By the treating physician: Skin response will be assessed immediately after treatment and at follow-up visits. Immediate and long-term adverse effects will be documented by the treating physicians during all treatment and follow-up visits. By the patient: To measure long-term adverse effects, the patient will complete a form at each follow-up visit assessing the following: change in color of the unaffected skin surrounding the treated area (lighter, darker, no change), formation of new scars (yes, no), and other side effects (free response). To measure short-term adverse effects, the patient will complete Part 2 of the post-treatment questionnaire within 72 hours of treatment, which evaluates swelling, bruising, scabbing, and blistering.
Time frame: From date of first treatment until study completion, assessed up to 52 weeks.
Exploratory Optical Coherence Tomography (OCT) Assessment of Treatment Response
Additional exploratory efficacy may be assessed using OCT imaging data. These evaluations will occur within the clinical setting following completion of the treatment series.
Time frame: From date of first treatment until study completion, assessed up to 52 weeks.
Plan to share: No
Started Jul 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.
Of 42 interventional studies with no phase under Rosacea, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's planned 29 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Irvine →